247 related articles for article (PubMed ID: 30213328)
1. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.
Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB
J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328
[TBL] [Abstract][Full Text] [Related]
2. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
[TBL] [Abstract][Full Text] [Related]
3. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
Van Der Meersch H; De Bacquer D; De Vriese AS
Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
[TBL] [Abstract][Full Text] [Related]
6. Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries.
Bonde AN; Lip GYH; Kamper AL; Staerk L; Torp-Pedersen C; Gislason G; Olesen JB
Thromb Haemost; 2017 Dec; 117(12):2291-2299. PubMed ID: 29212117
[TBL] [Abstract][Full Text] [Related]
7. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
Clin Ther; 2018 Jan; 40(1):114-122. PubMed ID: 29275065
[TBL] [Abstract][Full Text] [Related]
8. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
[TBL] [Abstract][Full Text] [Related]
9. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274
[TBL] [Abstract][Full Text] [Related]
10. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
[TBL] [Abstract][Full Text] [Related]
11. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
[TBL] [Abstract][Full Text] [Related]
12. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
14. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.
Olsen AS; McGettigan P; Gerds TA; Fosbøl EL; Olesen JB; Sindet-Pedersen C; Staerk L; Lock Hansen M; Pallisgaard JL; Køber L; Torp-Pedersen C; Gislason GH; Lamberts M
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):292-300. PubMed ID: 31742339
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
16. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
[TBL] [Abstract][Full Text] [Related]
17. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.
Pastori D; Farcomeni A; Saliola M; Del Sole F; Pignatelli P; Violi F; Lip GYH;
Eur J Intern Med; 2018 Aug; 54():34-39. PubMed ID: 29655807
[TBL] [Abstract][Full Text] [Related]
18. Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study.
Bonde AN; Blanche P; Staerk L; Gerds TA; Gundlund A; Gislason G; Torp-Pedersen C; Lip GYH; Hlatky MA; Olesen JB
Eur Heart J; 2019 Dec; 40(46):3782-3790. PubMed ID: 30932145
[TBL] [Abstract][Full Text] [Related]
19. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study.
Ording AG; Horváth-Puhó E; Adelborg K; Pedersen L; Prandoni P; Sørensen HT
Cancer Med; 2017 Jun; 6(6):1165-1172. PubMed ID: 28544489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
